Literature DB >> 30177297

Effects of human umbilical cord blood CD34+ cell transplantation in neonatal hypoxic-ischemia rat model.

Yan Yu1, YiZhong Yan1, Zhen Luo2, Pan Luo3, Na Xiao4, Xuan Sun5, LaMei Cheng6.   

Abstract

Perinatal brain injury can cause death in the neonatal period and lifelong neurodevelopmental deficits. Stem cell transplantation had been proved to be effective approach to ameliorate neurological deficits after brain damage. In this study we examine the effect of human umbilical cord blood CD34+ cells on model of neonatal rat hypoxic-ischemic brain damage and compared the neuroprotection of transplantation of CD34+ cells to mononuclear cells from which CD34+ cells isolated on neonatal hypoxic-ischemia rat model. Seven-day-old Sprague-Dawley rats were subjected to hypoxic-ischemic (HI) injury, CD34+ cells (1.5 × 104 cells) or mononuclear cells (1.0 × 106 cells) were transplanted into mice by tail vein on the 7 day after HI. The transplantation of CD34+ cells significantly improved motor function of rat, and reduced cerebral atrophy, inhibited the expression of glial fibrillary acidic protein (GFAP) and apoptosis-related genes: TNF-α, TNFR1, TNFR2, CD40, Fas, and decreased the activation of Nuclear factor kappa B (NF-κB) in damaged brain. CD34+ cells treatment increased the expression of DCX and lectin in ipsilateral brain. Moreover, the transplantation of CD34+ cells and MNCs which were obtained from the same amount of human umbilical cord blood had similar effects on HI. Our data demonstrated that transplantation of human umbilical cord blood CD34+ cells can ameliorate the neural functional defect and reduce apoptosis and promote nerve and vascular regeneration in rat brain after HI injury and the effects of transplantation of CD34+ cells were comparable to that of MNCs in neonatal hypoxic-ischemia rat model.
Copyright © 2018 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD34(+) cells; Cell therapy; Hypoxic-ischemic; Neuroprotection; Umbilical cord blood

Mesh:

Substances:

Year:  2018        PMID: 30177297     DOI: 10.1016/j.braindev.2018.08.007

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  7 in total

Review 1.  Rationale for the Use of Cord Blood in Hypoxic-Ischaemic Encephalopathy.

Authors:  Izabela Zdolińska-Malinowska; Dariusz Boruczkowski; Dominika Hołowaty; Paweł Krajewski; Emilian Snarski
Journal:  Stem Cells Int       Date:  2022-05-11       Impact factor: 5.131

Review 2.  Stem Cell Therapy for Pediatric Traumatic Brain Injury.

Authors:  Dana Lengel; Cruz Sevilla; Zoe L Romm; Jimmy W Huh; Ramesh Raghupathi
Journal:  Front Neurol       Date:  2020-12-02       Impact factor: 4.003

3.  Prevention and treatment of cerebral palsy with cord blood stem cells and cord-derived mesenchymal stem cells.

Authors:  Haruo Shintaku
Journal:  Neural Regen Res       Date:  2021-04       Impact factor: 5.135

Review 4.  Human umbilical cord blood mononuclear cells transplantation for perinatal brain injury.

Authors:  Yufeng Xi; Guang Yue; Shuqiang Gao; Rong Ju; Yujia Wang
Journal:  Stem Cell Res Ther       Date:  2022-09-05       Impact factor: 8.079

5.  Umbilical cord blood therapy modulates neonatal hypoxic ischemic brain injury in both females and males.

Authors:  Tayla R Penny; Yen Pham; Amy E Sutherland; Joohyung Lee; Graham Jenkin; Michael C Fahey; Suzanne L Miller; Courtney A McDonald
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

Review 6.  Hypoxic-ischemic-related cerebrovascular changes and potential therapeutic strategies in the neonatal brain.

Authors:  Clémence Disdier; Barbara S Stonestreet
Journal:  J Neurosci Res       Date:  2020-02-14       Impact factor: 4.164

7.  Effect of expansion of human umbilical cord blood CD34 + cells on neurotrophic and angiogenic factor expression and function.

Authors:  Ashalyn P Watt; Mark Kirkland; Lakshmi Nekkanti; Yen Pham; Courtney McDonald; Atul Malhotra; Guy Moeneclaey; Suzanne L Miller; Graham Jenkin
Journal:  Cell Tissue Res       Date:  2022-02-02       Impact factor: 5.249

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.